One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Cancer Cachexia Market

[ 英語タイトル ] Cancer Cachexia Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0083377
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
- Aeterna Zentaris
- Alder BioPharmaceuticals Inc.
- Aphios Corporation
- Bristol-Myers Squibb Company
- Pfizer
- GTx Inc.
- Helsinn Group
- Merck & Co. Inc.
- Novartis AG
- XBiotech Inc.

[Report Description]

Cancer cachexia is a wasting syndrome characterized by weight loss, anorexia, asthenia and anemia. Recently, due to the increasing prevalence of cancer and cancer cachexia, the demand for therapy drugs have increased globally. There is a rising demand in the market that has lead to increased research and development in discovery of therapeutic drugs. As a result, strong product pipeline has been built for the therapy products. Therefore all these factors have been primary reason for the growth of the market.

Moreover, increased awareness has regarding the illness and drugs has also helped the market growth. However, manufacturers of cancer cachexia drugs are discouraged from investing in the market because of the strict regulatory requirements and the long FDA approval procedure, which may impede the long-term growth of this market.

Key Market Trends

Combination Therapy is Expected to Dominate the Cancer Cachexia Market

Since cancer cachexia is defined as a multifactorial syndrome, an effective therapeutic approach is a comprehensive multi-faceted treatment that targets different pathophysiological mechanisms simultaneously. Past efforts to treat cachexia with nutritional or medical interventions may have disappointed because they were directed at a single domain of the syndrome, such as anorexia or muscle wasting, usually with a single therapeutic agent.

Preliminary trials combining pharmacological and non-pharmacological therapy have been shown to be feasible and also to improve selected clinical outcomes. The choice of specific pharmacological agents has varied based on mechanistic considerations or on prior promising single intervention or multimodal trials. As treatment provides a multi-faceted treatment for a complex illness, the development and research in the therapy is high. Therefore all these factors helps the market growth in the future.

North America is Expected to Dominate the Cancer Cachexia Market

The North American is expected to dominate the market due to the presence of large number of drug manufacturers and advancing paradigm of care for cancer patients that is supporting the growth in this region. Advancements in novel technology for the treatment of cancer cachexia and strong product pipeline for wasting syndrome has also helped in the growth of the cancer cachexia market in the region. Asia-Pacific is also estimated to grow at a higher CAGR due to the high prevalence and incidence of the cancer will lead to the expansion of the cancer cachexia market in this region.

Competitive Landscape

Majority of the cancer cachexia therapy drugs are being manufactured by the few key players. Product launches, acquisitions and R&D activities are key strategies adopted by players in the cancer cachexia market. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancer Cachexia
4.2.2 Strong R&D and Product Pipeline
4.3 Market Restraints
4.3.1 Stringent Regulatory Requirements
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Therapeutics
5.1.1 Progestogens
5.1.2 Corticosteroids
5.1.3 Combination Therapy
5.1.4 Others
5.2 By Mechanism of Action
5.2.1 Appetite Stimulators
5.2.2 Weight Loss Stabilizers
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Aeterna Zentaris
6.1.2 Alder BioPharmaceuticals Inc.
6.1.3 Aphios Corporation
6.1.4 Bristol-Myers Squibb Company
6.1.5 Pfizer
6.1.6 GTx Inc.
6.1.7 Helsinn Group
6.1.8 Merck & Co. Inc.
6.1.9 Novartis AG
6.1.10 XBiotech Inc.




Recommended reports